Blepharospasm is one of the most limiting symptoms in patients with Schwartz-Jampel syndrome and can affect early visual development, causing amblyopia and leading to disability. There is no consensus on the optimal management of blepharospasm in these patients. This systematic review aims to evaluate the current evidence for the appropriate management strategies for blepharospasm in Schwartz-Jampel syndrome.
Methods
This was a prospective register of systematic reviews (PROSPERO)-registered (CRD42024569495), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline-adherent systematic review. Databases searched include Medline (PubMed), Scopus, and Web of Science from any time to February 1st, 2025. All scientific manuscripts published discussing the management of blepharospasm in patients with Schwartz-Jampel syndrome were included. A novel therapeutic algorithm has been developed and proposed.
Results
From an initial number of 59 articles, 15 of them were included. No clinical trials nor observational studies were found. All these 15 articles were case series or case reports (quality of evidence: 4 or 5), involving 21 patients. A great heterogeneity in how to manage blepharospasm in Schwartz-Jampel syndrome was gathered. Therapeutic options included oral drugs (sodium channel blockers: carbamazepine, phenytoin, and procainamide), botulinum-toxin-A, and eyelid surgery (orbicularis myectomy). The management algorithm proposal is oral sodium channel blockers as the first option and eyelid surgery as the second option treatment. Botulinum-toxin-A might be considered a therapeutic step prior to surgery.
Conclusions
The published evidence regarding management strategies for blepharospasm in Schwartz-Jampel syndrome is scarce and of low quality. Since this nosology is a very rare disease, efforts should be promoted to conduct clinical research and a consensus document for the management of blepharospasm.
HoNCSanduskySMadikeV, et al.Clinico-pathogenetic findings and management of chondrodystrophic myotonia (Schwartz-Jampel syndrome): a case report. BMC Neurol2003; 3: 3.
6.
FerranniniEPerniolaTKrajewskaG, et al.Schwartz-Jampel syndrome with autosomal-dominant inheritance. Eur Neurol1982; 21: 137–146.
7.
NicoleSHamidaCBBeightonP, et al.Localization of the Schwartz–Jampel syndrome (SJS) locus to chromosome 1p34–p36.1 by homozygosity mapping. Hum Mol Genet1995; 4: 1633–1636.
8.
NicoleSDavoineCSTopalogluH, et al.Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet2000; 26: 480–483.
9.
Arikawa-HirasawaERossiSGRotundoRL,et al.Absence of acetylcholinesterase at the neuromuscular junctions of perlecan-null mice. Nat Neurosci2002; 5: 119–123.
10.
ViljoenDBeightonP. Schwartz-Jampel syndrome (chondrodystrophic myotonia). J Med Genet1992; 29: 58–62.
11.
CruzAAVSouzaCAPlastinoLS. Levator aponeurosis surgery in Schwartz-Jampel syndrome. Ophthal Plast Reconstr Surg1998; 14: 271–276.
12.
VargelICanterHITopalogluH,et al.Results of botilinum toxin: an application to blepharospasm in Schwartz-Jampel syndrome. J Craniofac Surg2006; 17: 656–660.
13.
MorrisonDAMellingtonFBHamadaS,et al.Schwartz-Jampel syndrome: surgical management of the myotonia-induced blepharospasm and acquired ptosis after failure with botulinum toxin A injections. Ophthal Plast Reconstr Surg2006; 22: 57–59.
14.
AryaRSharmaSGuptaN, et al.Schwartz Jampel syndrome in children. J Clin Neurosci2013; 20: 313–317.
15.
Carod ArtalFJFernandes SilvaTVChristino MarinhoPB,et al.Síndrome de Schwartz-Jampel: descripción de dos hermanos en edad adulta. Rev Neurol2002; 35: 131.
16.
EshraghiBShadravanMAalamiE,et al.Orbicularis oculi myectomy as a treatment for blepharospasm in a case of Schwartz Jampel syndrome. J Ophthalmic Vis Res2016; 11: 329.
17.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 11: n71.
18.
KeelSEvansJRBlockS, et al.Strengthening the integration of eye care into the health system: methodology for the development of the WHO package of eye care interventions. BMJ Open Ophthalmol2020; 5: e000533.
19.
SiddawayAPWoodAMHedgesLV. How to do a systematic review: a best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses. Annu Rev Psychol2019; 70: 747–770.
MoolaSMunnZTufanaruC, et al.Chapter 7: systematic reviews of etiology and risk. In: AromatarisEMunnZ (eds) Joanna Briggs institute reviewer’s manual. The Joanna Briggs Institute, 2017. https://reviewersmanual.joannabriggs.org/.
22.
BergerARCruessAFAltomareF, et al.Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica2015; 234: 6–25.
23.
HowickJChalmersIGlasziouP. OCEBM Levels of Evidence Working Group ‘The Oxford 2011 Levels of Evidence’: Oxford Centre for Evidence-Based Medicine. Oxford, 2011.
24.
TopaloğluHSerdaroğluAOkanM, et al.Improvement of myotonia with carbamazepine in three cases with the Schwartz-Jampel syndrome. Neuropediatrics1993; 24: 232–234.
25.
OzgeGUysalYMelih CeylanO,et al.Surgical management of 2 cases with Schwartz-Jampel syndrome. Can J Ophthalmol2015; 50: e110–e112.
26.
GurbuzGAlbayrakHM. Schwartz Jampel syndrome responding positively to carbamazepine therapy: a case report and a novel mutation. Turk J Pediatr2019; 61: 967–970.
27.
AburahmaSKAl-KhateebTAlrefaiA,et al.Botulinum toxin A injections for the treatment of Schwartz-Jampel syndrome: a case series. J Child Neurol2009; 24: 5–8.
28.
KashkouliMBShahrzadSJazayeriAA,et al.Treatment of blepharospasm in Schwartz-Jampel syndrome: botulinum toxin A injection or surgery. Ophthal Plast Reconstr Surg2017; 33: S47–S49.
29.
SuphatsathienkulPSakpichaisakulKWechapinanT, et al.Successful treatment of Schwartz-Jampel syndrome with botulinum toxin type A. Dermatol Ther2024; 14: 545–556.
30.
DingJXuYYuanB,et al.Management of blepharospasm and blepharophimosis associated with Schwartz-Jampel syndrome. J Am Assoc Pediatr Ophthalmol Strabismus2021; 25: 54–56.
31.
LucciLMYenMTAndersonRL, et al.Orbicularis myectomy with levator advancement in Schwartz-Jampel syndrome. Am J Ophthalmol2001; 132: 799–801.
32.
PatrinelyJRAndersonRL. Acquired blepharophimosis in a patient with juvenile blepharospasm. Ophthal Plast Reconstr Surg1986; 2: 205–208.
33.
SpaansFWagenmakersASarisW, et al.Procainamide therapy, physical performance and energy expenditure in the Schwartz-Jampel syndrome. Neuromuscul Disord1991; 1: 371–374.
34.
PascuzziRMGratianneRAzzarelliB,et al.Schwartz-Jampel syndrome with dominant inheritance. Muscle Nerve1990; 13: 1152–1163.
35.
SquiresLAPrangleyJ. Neonatal diagnosis of Schwartz-Jampel syndrome with dramatic response to carbamazepine. Pediatr Neurol1996; 15: 172–174.
36.
Arikawa-HirasawaELeAHNishinoI, et al.Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet2002; 70: 1368–1375.
37.
GubbiottiMANeillTIozzoRV. A current view of perlecan in physiology and pathology: a mosaic of functions. Matrix Biol2017; 57–58: 285–298.
38.
PengHBXieHRossiSG,et al.Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan. J Cell Biol1999; 145: 911–921.
39.
NishimuneHShigemotoK. Practical anatomy of the neuromuscular junction in health and disease. Neurol Clin2018; 36: 231–240.
40.
GiedionABoltshauserEBrinerJ, et al.Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia. Eur J Pediatr1997; 156: 214–223.
41.
Arikawa-HirasawaEWilcoxWRLeAH, et al.Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet2001; 27: 431–434.
42.
Lehmann-HornFIaizzoPAFrankeC, et al.Schwartz-Jampel syndrome: iI. Na+ channel defect causes myotonia. Muscle Nerve1990; 13: 528–535.
SeayARZiterFA. Malignant hyperpyrexia in a patient with Schwartz-Jampel syndrome. J Pediatr1978; 93: 83–84.
45.
AyekoMO. Schwartz–Jampel syndrome: is risk of malignant hyperthermia the same as that of the general population?Saudi J Anaesth2018; 12: 498–499.
46.
EL-MollaA. Schwartz-Jampel syndrome is a high risk of difficult airway management rather than malignant hyperthermia. Saudi J Anaesth2022; 16: 519–520.
47.
EikermannMBredendiekMSchaperJ, et al.Resistance to rocuronium in a child with Schwartz-Jampel syndrome type 1 B. Neuropediatrics2002; 33: 43–46.
48.
ZeppieriMAmeerMAJahngirMU, et al.Meige syndrome. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2025 [cited 2025 May 20]. http://www.ncbi.nlm.nih.gov/books/NBK513358/.
49.
LaiCSWangYCRamachandranS, et al.Selective myectomy and myotomy in situ for the management of refractory blepharospasm in Meige syndrome. Ann Plast Surg2023; 90: S84–S88.
50.
LaiHTChenADLeeSS, et al.Myotomy in situ for essential blepharospasm refractory to botulinum toxin. Ann Plast Surg2020; 84: S74–S79.
51.
SchiavoGSantucciADasguptaBR, et al.Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett1993; 335: 99–103.
52.
SalariMSharmaSJogMS. Botulinum toxin induced atrophy: an uncharted territory. Toxins (Basel)2018; 10: 313.
53.
WitmanowskiHBłochowiakK. The whole truth about botulinum toxin – a review. Adv Dermatol Allergol2019; 37: 853–861.
54.
ElsayedSMGamalR. An Egyptian patient with Schwartz-Jampel syndrome type I and new ocular findings. Egypt J Med Hum Genet2017; 18: 393–396.
55.
SubramanianSShettyD. Anaesthetic management of a child with Schwartz-Jampel syndrome for botox injection - a case study. Indian J Anaesth2023; 67: 752–753.
56.
SharawatIKKasinathanASutharR,et al.Herculean boy with facial myokymia. Pediatr Neurol2019; 96: 79–80.
AlterKE. High-frequency ultrasound guidance for neurotoxin injections. Phys Med Rehabil Clin NM2010; 21: 607–630.
59.
ScaffMMendonçaLILevyJA,et al.Chondrodystrophic myotonia: electromyographic and cardiac features of a case. Acta Neurol Scand1979; 60: 243–249.
60.
EdwardsWCRootAW. Chondrodystrophic myotonia (Schwartz-Jampel syndrome): report of a new case and follow-up of patients initially reported in 1969. Am J Med Genet1982; 13: 51–56.
61.
van HuffelenACGabreĕlsFJLuypen-vd HorstJS, et al.Chondrodystrophic myotonia. A report of two unrelated Dutch patients. Neuropadiatrie1974; 5: 71–90.
62.
Carod-ArtalFJFernandes da SilvaTVChristino-MarinhoPB,et al.Schwartz-Jampel syndrome: a description of two adult siblings. Rev Neurol2002; 35: 131–134.
63.
AtmacaFGAkgün DoğanÖKutlubayB,et al.Schwartz-Jampel syndrome type-1: compound heterozygosity of two novel variants. J Clin Res Pediatr Endocrinol2024.
64.
BandeiraIDJagersbacherJGBarrettoTL, et al.Botulinum toxin type A in the treatment of facial myotonia in Schwartz-Jampel syndrome. Muscle Nerve2017; 56: E10–E11.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
